NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

A lot of old ground being dug up.

Is this old ground too?

Forget for a moment that there is a control arm. Forget there is a placebo.

Focus only on the original treatment arm in the main 348 group of the phase III DCVax-L trial.

Upon progression, isn't it a somewhat novel concept that DCVax-L, a dendritic immunotherapy, is not necessarily stopped at that point, instead it can be increased back to original intensity -- e.g. 0th, 10th then 30th day, etc?

Consider if that were the case in the upcoming phase II direct trial. Upon progression, patients received renewed intensified dosing -- as opposed to being taken off dosing.

Does anyone agree it may be very important to know what affect if any that reintensified/second round dosing had on patients' tumor response, immune response and survival in the current DCVax-L trial?

I do, and I think it it will be extremely important information taken into consideration when putting the final touches on the phase II trials. For instance, it may determine whether sarcoma remains a phase II study indication -- I hope it does.

(Note: Following AstraZeneca news, I'd expect/speculate bladder cancer may be added to the phase II DCVax-Direct trial list relatively soon.)